NCT00660660已完成4 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 276
- 试验地点
- 1
- 主要终点
- Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study.
研究概览
简要总结
The purpose of this research study is to compare the safety and effectiveness (how well the medicine works) of esomeprazole (study drug) to placebo (a capsule that does not contain any medication) taken daily in relieving nighttime heartburn and problems sleeping in patients with gastroesophageal reflux disease (GERD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prior to the run-in period, a history of heartburn or acid regurgitation for 3 months or longer or any history of EE;
- •Prior to the run-in period, nighttime heartburn averaging at least 2 or 3 times per week;
- •Prior to the run-in period, a history of sleep disturbances associated with GERD for 1 month or more;
排除标准
- •Any condition other than GERD that is either the primary cause of, or a significant contributor to, the patient's sleep disturbance
- •Sleep medication (including over-the-counter), antihistamine, benzodiazepine, or anti-anxiety medication use that has not been stable (either in dose or regularity) for at least 3 months or is not expected to remain stable during the patient's participation in the study. Patients on a stable regimen, whose regimen is also expected to remain stable throughout the study, are eligible for participation;
- •Proton Pump Inhibitor (PPI) use within 1 week prior to Screening. The only allowable acid modifying rescue medication is GELUSIL® during the run-in period. Only study medication and rescue medication (GELUSIL®) is allowed during the treatment period for treatment of acid mediated symptoms
研究组 & 干预措施
Nexium 20mg
Experimental
Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
干预措施: Esomeprazole (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study.
时间窗: Days 21- 28 (for early dropouts the last 7 days staying in the study)
Relief of nighttime heartburn on patient's last 7 days in the study. Relief was defined as a daily diary card response of "none" or 0, on at least 6 of 7 days, allowing for one "mild" or 1 response. Diary card scale (none, mild, moderate, severe).
次要结局
- Achievement of Developer-defined Good Sleep(4 weeks)
- Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment.(1 week)
- Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment.(4 weeks)
- Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment(4 weeks)
- Number of Days to First Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period(4 weeks)
- Percentage of Patients With Complete Resolution of Daytime Heartburn After 1 Week of Treatment(1 week)
- Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment(1 week)
- Number of Days to First Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period(4 weeks)
- Percentage of Patients With Complete Resolution of Daytime Heartburn After 4 Weeks of Treatment(4 weeks)
- Percentage of Patients With Complete Resolution of Daytime Heartburn on the Patient's Last 7 Days in the Study(Days 21- 28 (for early dropouts the last 7 days staying in the study))
- Change in Mean (Average) Pittsburgh Sleep Quality Index (PSQI) Scores From Baseline(Baseline and 4 weeks)
- Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment.(2 weeks)
- Percentage of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.(Days 21- 28 (for early dropouts the last 7 days staying in the study))
- Number of Days to Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period(4 weeks)
- Percentage of Patients With Complete Resolution of Nighttime Heartburn After 1 Week of Treatment.(1 week)
- Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.(Days 21- 28 (for early dropouts the last 7 days staying in the study))
- Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment(2 weeks)
- Percentage of Days Without Gastroesophageal Reflux Disease (GERD)-Related Sleep Disturbances During the 4 Week Period(4 weeks)
- Percentage of Patients With Relief of Nighttime Heartburn After 1 Week of Treatment.(1 week)
- Percentage of Patients With Relief of 24-hour Heartburn on the Patient's Last 7 Days in the Study(Days 21- 28 (for early dropouts the last 7 days staying in the study))
- Percentage of Patients With Nighttime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study(Days 21- 28 (for early dropouts the last 7 days staying in the study))
- Percentage of Patients With Complete Resolution of Daytime Heartburn After 2 Weeks of Treatment(2 weeks)
- Percentage of Patients With Complete Resolution of 24-hour Heartburn After 2 Weeks of Treatment(2 weeks)
- Percentage of Patients With Complete Resolution of 24-hour Heartburn After 4 Weeks of Treatment(4 weeks)
- Percentage of Patients With Relief of Daytime Heartburn After 2 Weeks of Treatment(2 weeks)
- Percentage of Patients With Relief of Daytime Heartburn After 4 Weeks of Treatment(4 weeks)
- Percentage of Patients With Relief of Nighttime Heartburn After 4 Weeks of Treatment(4 weeks)
- Percentage of Participants With Daytime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study(Days 21-28 (for early dropouts the last 7 days staying in the study))
- Equivalent Number of Hours Lost Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)(4 weeks)
- Change From Baseline in Percent of Work Impairment Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)(Baseline and 4 weeks)
- Change From Baseline in Percent Activity Impairment Due to Sleep Disturbances (Average)(Baseline and 4 weeks)
- Percentage of Patients With Complete Resolution of Nighttime Heartburn After 2 Weeks of Treatment(2 weeks)
- Percentage of Patients With Relief of Daytime Heartburn After 1 Week of Treatment(1 week)
- Percentage of Patients With Relief of Nighttime Heartburn After 2 Weeks of Treatment(2 weeks)
- Percentage of Patients With Relief of 24-hour Heartburn After 2 Weeks of Treatment(2 weeks)
- Percentage of Patients With Relief of 24-hour Heartburn After 4 Weeks of Treatment(4 weeks)
- Percentage of Patients With Complete Resolution of Nighttime Heartburn on the Patient's Last 7 Days in the Study.(Days 21- 28 (for early dropouts the last 7 days staying in the study))
- Percentage of Patients With Complete Resolution of 24-hour Heartburn on the Patient's Last 7 Days in the Study(Days 21- 28 (for early dropouts the last 7 days staying in the study))
- Percentage of Patients With Relief of 24-hour Heartburn After 1 Week of Treatment(1 week)
- Percentage of Patients With 24-hour Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study.(Days 21- 28 (for early dropouts the last 7 days staying in the study))
- Percentage of Patients With Complete Resolution of Nighttime Heartburn After 4 Weeks of Treatment(4 weeks)
- Percentage of Patients With Complete Resolution of 24-hour Heartburn After 1 Week of Treatment(1 week)
- Percentage of Patients With Relief of Daytime Heartburn on the Patient's Last 7 Days in the Study(Days 21- 28 (for early dropouts the last 7 days staying in the study))
- Percentage of Patients With Relief of Nighttime Heartburn on the Patient's Last 7 Days in the Study(Days 21- 28 (for early dropouts the last 7 days staying in the study))
- Monetary Value of Work Hours Saved(Week 4)
- Change From Baseline in Percent Overall Work Impairment Due to Sleep Disturbance (Average)(Baseline and 4 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisNCT00650078Amgen350
已完成
3 期
MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)Type 2 Diabetes MellitusNCT00289848Merck Sharp & Dohme LLC530
已完成
2 期
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)Acute Spinal Cord InjuryNCT01502631Daiichi Sankyo65
已完成
3 期
An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)Aortic StenosisNCT00092677Organon and Co1,873
Unknown
2 期
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH CirrhosisDecompensated CirrhosisNCT03205345Conatus Pharmaceuticals Inc.210